Market Overview

William Blair Upgrades PTC Therapeutics On Risdiplam Prospects

Share:
William Blair Upgrades PTC Therapeutics On Risdiplam Prospects

PTC Therapeutics, Inc. (NASDAQ: PTCT) traded sigificantly higher Monday after having published a positive update from its risdiplam trial in type 1 SMA babies.

The Rating

William Blair analyst Raju Prasad accordingly upgraded PTC to Outperform.

The Thesis

Risdiplam’s efficacy data compares favorably with that of Spinraza, and the drug also boasts superior convenience and strong tolerability.

“Risdiplam results shown at CureSMA give us increased confidence that the drug is achieving a clinical benefit and while Roche is responsible for commercialization, we believe that, if successful, risdiplam could conservatively net about $150 million in peak royalties to PTC as well as an additional $410 million in remaining milestones,” Prasad wrote in a note.

The prospects for risdiplam compound additional opportunities for Translarna’s label and geographic market expansion.

Translarna recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use to expand the patient range. PTC has projected 2018 revenue of $170 million to $185 million with 15-percent compound annual growth through 2022.

“Overall, we believe that PTC has several promising pipeline therapies, highlighted by the presentations of its programs in Huntington's disease, familial dysautonomia, spinal muscular atrophy, and oncology (PTC596 and PTC299), and we will continue to monitor these preclinical programs as they advance into the clinic,” Prasad wrote.

Price Action

At time of publication, PTC shares were trading up 26 percent at a rate of $47.32.

Related Links:

Verastem Shares Hit Highest Level Since 2015 On Duvelisib Data

Intellia Confirms Crispr Risk Irrelevant To Its Program, With No Adjustments Needed

Latest Ratings for PTCT

DateFirmActionFromTo
Apr 2019BernsteinInitiates Coverage OnOutperform
Nov 2018Cantor FitzgeraldMaintainsOverweightOverweight
Nov 2018RBC CapitalMaintainsOutperformOutperform

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

Posted-In: Raju Prasad Risdiplam Spinraza TranslarnaAnalyst Color Upgrades Top Stories Analyst Ratings Best of Benzinga

 

Related Articles (PTCT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
COMMJP MorganInitiates Coverage On0.0
KEYWSunTrust Robinson HumphreyDowngrades0.0
ISRGCanaccord GenuityMaintains575.0
PBCTFig PartnersDowngrades0.0
CNSGabelli & Co.Downgrades0.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Small-Cap ETFs Climb As Volatility Ebbs

Buckingham: Quad/Graphics Is The 'Clear Best Of Breed' In Commercial Print